Evaluation of a modified double-disc synergy test for detection of extended spectrum β-lactamases in AmpC β-lactamase-producing Proteus mirabilis

Indian Journal of Medical Microbiology

Volumn 26, Issue 1, 2008, Pages 58-61

  Khan, M K R ^a   Thukral, S ^a   Gaind, R ^b  

^a UNIVERSITY OF DELHI   (India)

^b SAFDARJUNG HOSPITAL   (India)

Author keywords

AmpC lactamase; Extended spectrum lactamase detection; Proteus mirabilis

Indexed keywords

BETA LACTAMASE AMPC; CEFEPIME; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CEPHALOSPORIN; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; PIPERACILLIN PLUS TAZOBACTAM;

ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATE; BROTH DILUTION; COMPARATIVE STUDY; CONTROLLED STUDY; EVALUATION; LABORATORY; MODIFIED DOUBLE DISC SYNERGY TEST; NONHUMAN; PHENOTYPE; PROTEUS MIRABILIS; SCREENING; STANDARD;

EID: 38849104417     PISSN: 02550857     EISSN: 02550857     Source Type: Journal    
DOI: 10.4103/0255-0857.38860     Document Type: Article

References (13)

1. Thomson KS. Controversies about extended-spectrum and AmpC beta-lactamases. Emerg Infect Dis 2001;7:333-6.
2. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.
3. Ho PL, Ho AY, Chow KH, Wong RC, Duan RS, Ho WL, et al. Occurrence and molecular analysis of extended spectrum β-lactamase-producing Proteus mirabilis in Hong Kong, 1999-2002. J Antimicrob Chemother 2005;55:840-5.
4. Manchanda V, Singh NP. Occurrence and detection of AmpC β-lactamases among gram negatve clinical isolates using a modified three dimensional test at Guru Tegh Bahadur Hospital, Delhi, India. J Antimicrob Chemother 2003;51:415-8.
5. Singhal S, Mathur T, Khan S, Upadhyay DJ, Chugh S, Gaind R, et al. Evaluation of methods for AmpC β-lactamase in gram negative clinical isolates from tertiary care hospitals. Indian J Med Microbiol 2005;23:120-4.
6. Naas T, Benaoudia F, Massuard S, Nordmann P. Integron located VEB-1 extended spectrum β-lactamase gene in a Proteus mirabilis clinical isolate from Vietnam. J Antimicrob Chemother 2000;46:703-11.
7. Pitout JD, Reisbig MD, Venter EC, Church DL, Hanson ND. Modification of the double disc test for detection of Enterobacteriaceae producing extended spectrum and AmpC β-lactamases. J Clin Microbiol 2003;41:3933-5.
8. Thomson KS, Sanders CC, Moland ES. Use of microdilution panels with and without β-lactamase inhibitors as a phenotypic test for β-lactamase production among Escherichia coli, Klebsiella spp, Enterobacter spp, Citrobacter freundiim and Serratia marcescens. Antimicrob Agents Chemother 1999;43:1393-400.
9. Jarlier V, Nicolas M, Fournier G, Philippon A. Extended spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: Hospital prevalence and susceptibility patterns. Rev Infect Dis 1988;10:867-78.
10. Clinical and Laboratory Standards Institute. 2005 guidelines by CLSI/NCCLS - CLSI informational supplement. Approved standard M100-S15 Wayne, PA; 2000.
11. Shukla I, Tiwari R, Agrawal M. Prevalence of extended spectrum β-lactamase producing Klebsiella pneumoniae in a Tertiary Care Hospital. Indian J Med Microbiol 2004;22:87-91.
12. De Gheldre Y, Avesani V, Berhin C, Delmée M, Glupczynski Y. Evaluation of the oxoid combination discs for detection of extended spectrum β-lactamases. J Antimicrob Chemother 2003;52:591-7.
13. Luzzaro F, Perilli M, Amicosante G, Lombardi G, Belloni R, Zollo A, et al. Properties of multidrug-resistant, ESBL producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations. Int J Antimicrob Agents 2001;17:131-5.